

activities on behalf of the Secretary of the U.S. Department of Health and Human Services (HHS), with the exception of the regulatory research integrity activities of the Food and Drug Administration. ORI is a program office within the Office of the Assistant Secretary for Health, Office of the Secretary, HHS.

Core to ORI's mission is the support of education and outreach activities that aid PHS-funded research institutions in their efforts "to teach the responsible conduct of research, promote research integrity, prevent research misconduct, and . . . to respond effectively to allegations of research misconduct" (65 FR 30600, 30601 (May 12, 2000)). ORI Events contribute to this mission by providing education, training, and/or the opportunity for discussion related to topics such as handling allegations of research misconduct and fostering research integrity and the responsible conduct of research. ORI Events typically are moderately sized, usually accepting between 20 and 150 attendees, and convened in person or virtually for one to three days.

Co-sponsors will work with ORI staff to jointly develop an event. Both ORI and the co-sponsor must contribute substantively to the development of the event. Co-sponsors can charge registration fees to recover costs associated with the events; however, co-sponsors may not set registration fees at an amount higher than necessary to recover event-related expenses. Further, co-sponsors are solely responsible for collecting and handling any registration fees.

**Eligibility for Co-Sponsorship:** The co-sponsoring entity must have demonstrated interest and experience in fostering the responsible conduct of research or handling of research misconduct allegations. The co-sponsoring entity must participate substantively in the co-sponsored activity, and not just provide funding, logistical services, or other material support.

**Expression of Interest in Co-Sponsorship:** An entity shall provide an expression of interest that includes (1) one to two paragraphs detailing why ORI should select the entity, including the entity's leadership in and management of matters involving research integrity and the responsible conduct of research, and (2) a bulleted outline addressing the seven topics listed below. The expression of interest should be one to two pages in length, single-spaced, and at least 11-point font. An entity may submit an expression of interest individually or jointly with other entities describing their relative

contributions. The seven topics to be addressed in the outline are:

1. The entity's interest and goals in promoting research integrity and/or the responsible conduct of research
2. The entity's prior experience and current readiness to undertake the responsibilities described above
3. The type of event(s) that the entity is interested in co-sponsoring with ORI
4. Facilities available for the event(s), including the distance from the facilities to a major airport
5. Any current constraints with respect to dates or facilities
6. Whether the entity has co-sponsored an ORI Event in the past 36 months
7. Whether the entity has any cases, allegations, or other related matters pending with ORI

**Evaluation Criteria:** After engaging in exploratory discussions with potential co-sponsors who respond to this notice, HHS will apply the following considerations, as appropriate and relevant, to select the co-sponsor(s):

- Qualifications and capability to fulfill co-sponsorship responsibilities
- Suitability of the location of the proposed event in terms of the overall geographical distribution of recent or planned ORI Events
- Potential for reaching, generating, and engaging an adequate number of attendees
- Availability and description of facilities needed to support the event
- Availability of administrative support for the logistics of hosting such events

The duties of the co-sponsor will be outlined in a co-sponsorship agreement with ORI that will set forth the details of the co-sponsored event, including the requirements that any fees collected by the co-sponsor shall be limited to the amount necessary to cover the co-sponsor's event-related expenses. This co-sponsorship agreement does not represent an endorsement by ORI of an individual co-sponsor's policies, positions, or activities.

Dated: October 13, 2022.

**Wanda K. Jones,**

*Acting Director, Office of Research Integrity,  
Office of the Assistant Secretary for Health.*

[FR Doc. 2022-22887 Filed 10-20-22; 8:45 am]

**BILLING CODE 4150-31-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Proposed Collection; 60-Day Comment Request, National Institute on Drug Abuse (NIDA) Summer Research Internship Program

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Dr. Wilson Compton, Acting Director, Office of Research Training, Diversity, and Disparities, National Institute on Drug Abuse, 3WFN, 11601 Landsdown St., Room 09D18, North Bethesda, Maryland, 20892 or call non-toll-free number (301) 443-6480 or Email your request, including your address, to: [Wilson.Compton@nih.gov](mailto:Wilson.Compton@nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of

appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Proposed Collection Title:* NIDA Summer Research Internship Program, 0925–0738, Expiration 12/31/2022, EXTENSION, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH).

*Need and Use of Information Collection:* The purpose of the proposed information is for the selection of interns for the continuing NIDA Summer Research Internship Program.

This request is to allow NIDA to collect information from applicants in order to meet the goals of the program and IC mission. Applicant eligibility for this program is for those age 18 and over in the year of application per NIH policy document.

*NIDA Summer Research Internship Program (NIDA–SIP) Policy.* NIDA will request clearance for any additional forms should new programs be introduced in the future.

The information ensures that students applying to this program meet basic eligibility requirements; indicates their

interest in substance abuse research, future career goals, and, if selected for the program, what research they prefer to conduct. The information also enables decision-making regarding which applicants will be selected for internships. In each case, completing the application is voluntary, but in order to receive due consideration, the prospective applicant must complete all fields required by the program. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 300.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Form	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Estimated total annual burden hours
Summer Internship .....	Individuals-household .....	300	1	1	300
Total .....	.....	.....	300	.....	300

Dated: October 18, 2022.

**Lanette A. Palmquist,**

*Project Clearance Liaison, National Institute on Drug Abuse, National Institutes of Health.*

[FR Doc. 2022–22960 Filed 10–20–22; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Healthcare Delivery and Methodologies Integrated Review Group; Population and Public Health Approaches to HIV/AIDS Study Section.

*Date:* November 14–15, 2022.

*Time:* 8:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

*Contact Person:* Jose H. Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5222, MSC 7852, Bethesda, MD 20892, 301–435–1137, [guerriej@csr.nih.gov](mailto:guerriej@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Musculoskeletal, Orthopedic, Oral, Dermatology and Rheumatology.

*Date:* November 15–16, 2022.

*Time:* 8:30 a.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Aftab A. Ansari, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, (301) 237–9931, [ansaria@csr.nih.gov](mailto:ansaria@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Small Business: Drug Discovery Involving the Nervous System.

*Date:* November 15–16, 2022.

*Time:* 9:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Lai Yee Leung, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1011D, Bethesda, MD 20892, (301) 827–8106, [leungl2@csr.nih.gov](mailto:leungl2@csr.nih.gov).

*Name of Committee:* Infectious Diseases and Immunology B Integrated Review Group;

HIV Comorbidities and Clinical Studies Study Section.

*Date:* November 15–16, 2022.

*Time:* 9:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20876 (Virtual Meeting).

*Contact Person:* David C. Chang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 451–0290, [changdac@mail.nih.gov](mailto:changdac@mail.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; RFA–RM–22–024: Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases.

*Date:* November 15–16, 2022.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Vandana Kumari, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–3290, [vandana.kumari@nih.gov](mailto:vandana.kumari@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Topics in Virology.

*Date:* November 15–16, 2022.

*Time:* 10:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Sharon Isern, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 810J,